The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.

Hurwitz MD. The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer. Transl Androl Urol. 2019 Jul; 8(Suppl 3):S303-S306.

View in: PubMed